Tablet Burden Lowest with Lanthanum Carbonate

Share this content:

This article is part of our ongoing coverage of Renal Week 2009. Click here for a complete list of our Renal Week Live articles.


Key Points

  • CKD patients who used lanthanum carbonate to manage hyperphosphatemia had a lower mean tablet burden than those who took sevelamer hydrochloride or calcium acetate.
  • Patients on lanthanum carbonate on average took four tablets a day compared with seven for sevelamer hydrochloride users and six for those taking calcium acetate.
  • Greater tablet burden does not result in improved incremental phosphate control.

CKD patients who used lanthanum carbonate to manage hyperphosphatemia had a lower mean tablet burden than those who took sevelamer hydrochloride or calcium acetate, according to researchers who presented a study at ASN's Renal Week 2009.

The study, led by Michael S. Keith, PhD, PharmD, of Shire Pharmaceuticals, which makes lanthanum carbonate, included 4,137 patients, of whom 393 (9%) used lanthanum carbonate, 1,955 (47%) used sevelamer hydrochloride, and 1,790 (44%) used calcium acetate.

Patients on lanthanum carbonate on average took four tablets a day compared with seven for sevelamer hydrochloride users and six for those taking calcium acetate. At therapy discontinuation, a higher proportion of patients on lanthanum carbonate had achieved phosphate control (a level of 5.5 mg/dL or less) compared with users of sevelamer hydrochloride or calcium acetate. Thus, the researchers concluded that greater tablet burden does not result in improved incremental phosphate control

The mean cost per patient per month was $419 for lanthanum carbonate, $447 for sevelamer hydrochloride, and $84 for calcium acetate.

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters